ARCT (Arcturus Therapeutics Holdings) Cyclically Adjusted Revenue per Share: $4.32 (As of Mar. 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
56 GF Score
Price $7.51
GF Value $4.10
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Cyclically Adjusted Revenue per Share?

Arcturus Therapeutics Holdings ARCT +2.18% 56 Cyclically Adjusted Revenue per Share is $4.32 as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 56/100 and a GF Value™ of $4.10 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Arcturus Therapeutics Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was $0.021. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.32 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Arcturus Therapeutics Holdings's average Cyclically Adjusted Revenue Growth Rate was -6.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Arcturus Therapeutics Holdings was 12.90% per year. The lowest was 2.80% per year. And the median was 7.85% per year.

As of today (2026-07-07), Arcturus Therapeutics Holdings's current stock price is $7.51. Arcturus Therapeutics Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $4.32. Arcturus Therapeutics Holdings's Cyclically Adjusted PS Ratio of today is 1.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arcturus Therapeutics Holdings was 11.64. The lowest was 1.34. And the median was 4.72.


Arcturus Therapeutics Holdings  (NAS:ARCT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arcturus Therapeutics Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.51/4.32
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arcturus Therapeutics Holdings was 11.64. The lowest was 1.34. And the median was 4.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Arcturus Therapeutics Holdings Cyclically Adjusted Revenue per Share Related Terms


Arcturus Therapeutics Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings Cyclically Adjusted Revenue per Share Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.18 4.00 4.38 4.58 4.35

Arcturus Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.62 4.63 4.59 4.35 4.32

ARCT vs MDWD, UNCY, EQ: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Cyclically Adjusted PS Ratio falls into.


ARCT
56GF Score
Arcturus Therapeutics Holdings Inc ARCT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arcturus Therapeutics Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.021/330.2130*330.2130
=0.021

Current CPI (Mar. 2026) = 330.2130.

Arcturus Therapeutics Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 5.176 241.432 7.079
201703 0.000 243.801 0.000
201706 1.851 244.955 2.495
201709 1.570 246.819 2.100
201712 0.190 246.524 0.255
201803 0.236 249.554 0.312
201806 0.237 251.989 0.311
201809 0.339 252.439 0.443
201812 0.750 251.233 0.986
201903 0.431 254.202 0.560
201906 0.975 256.143 1.257
201909 0.251 256.759 0.323
201912 0.204 256.974 0.262
202003 0.182 258.115 0.233
202006 0.124 257.797 0.159
202009 0.102 260.280 0.129
202012 0.090 260.474 0.114
202103 0.081 264.877 0.101
202106 0.076 271.696 0.092
202109 0.093 274.310 0.112
202112 0.220 278.802 0.261
202203 0.199 287.504 0.229
202206 1.025 296.311 1.142
202209 0.505 296.808 0.562
202212 5.499 296.797 6.118
202303 2.937 301.836 3.213
202306 0.360 305.109 0.390
202309 1.632 307.789 1.751
202312 0.935 306.746 1.007
202403 1.213 312.332 1.282
202406 1.705 314.175 1.792
202409 1.434 315.301 1.502
202412 0.775 315.605 0.811
202503 0.940 319.799 0.971
202506 0.903 322.561 0.924
202509 0.521 324.800 0.530
202512 0.110 324.054 0.112
202603 0.021 330.213 0.021

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.32 mean?
Arcturus Therapeutics Holdings (ARCT) has a Cyclically Adjusted Revenue per Share of $4.32 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arcturus Therapeutics Holdings and its competitors.
Is Arcturus Therapeutics Holdings' Cyclically Adjusted Revenue per Share too high?
Arcturus Therapeutics Holdings' current Cyclically Adjusted Revenue per Share is $4.32. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Cyclically Adjusted Revenue per Share compare to MDWD and UNCY?
Arcturus Therapeutics Holdings' Cyclically Adjusted Revenue per Share of $4.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current Cyclically Adjusted Revenue per Share is $4.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.10, compared to a current price of $7.51 — trading 83.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.32. Arcturus Therapeutics Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Cyclically Adjusted Revenue per Share is $4.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $7.51 is trading 83.2% above its estimated GF Value™ of $4.10. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Cyclically Adjusted Revenue per Share: $4.32
  • GF Value™: $4.10 vs. price of $7.51 (83.2% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
56GF Score

Get the complete analysis for ARCT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.51
Price
$4.10
GF Value